By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Novartis AG 

Lichtstrasse 35

Basel    CH-4056  Switzerland
Phone: 41-0-61-3241111 Fax: 41-0-61-3248001


SEARCH JOBS

Novartis is located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

For more information, visit
www.novartis.com and follow us on www.twitter.com/Novartis

YEAR FOUNDED:

1996

LEADERSHIP:

CEO: Joseph Jimenez

CMO: Vasant (Vas) Narasimhan

CFO: Harry Kirsch

JOBS:

Please click here for Novartis job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products

FOLLOW NOVARTIS:








Key Statistics


Email:
Ownership: Subsidiary

Web Site: Novartis AG
Employees:
Symbol: NVS
 



Industry
Services






Company News
Novartis AG (NVS) CEO Plays Down Prospects For Actelion (ALIOF.PK) Bid 12/7/2016 7:55:44 AM
So Long, Farewell: Head of Novartis AG (NVS)'s Shuttered CAR-T Unit to Helm Biotech Upstart Tmunity 12/7/2016 7:41:54 AM
Novartis AG (NVS) Announces Zykadia First-Line Study Results Showing 16.6 Month Progression-Free Survival In Patients With ALK+ Advanced NSCLC 12/6/2016 8:12:02 AM
Novartis AG (NVS) Data Shows Treatment-Free Remission Rates Are Consistently Above 50% Regardless Of Reason For Switch To Tasigna From Gleevec 12/6/2016 6:55:54 AM
Novartis AG (NVS) SEG101 (Crizanlizumab, formerly SelG1) Significantly Reduces Frequency Of Sickle Cell Pain Crises In Phase II Study 12/5/2016 11:19:05 AM
Novartis AG (NVS) Presents Results From First Global Registration Trial Of CTL019 In Pediatric And Young Adult Patients With R/R B-ALL 12/5/2016 10:38:23 AM
Novartis AG (NVS)' $665 Million Bet Pays Off as Selexys Shows Off New Phase II Data 12/5/2016 5:37:33 AM
Novartis AG (NVS)’ CAR-T Drug Sends 82% of Patients’ Blood Cancer into Remission, Eyes 2017 for Marketing 12/5/2016 5:27:13 AM
Novartis AG (NVS) Rumored to be Exploring Sale of Ritalin, Clozaril and Exelon, Deal Could Bring in $300 Million 11/23/2016 5:52:31 AM
'Retired' Former Novartis AG (NVS) R&D Cancer Head Returns for a New Gig at the Dana-Farber Cancer Institute 11/23/2016 5:43:14 AM
12345678910...
//-->